Literature DB >> 10571271

Preparation, purification, and characterization of a reversibly lipidized desmopressin with potentiated anti-diuretic activity.

J Wang1, D Shen, W C Shen.   

Abstract

PURPOSE: . To prepare and characterize a reversibly lipidized dipalmitoyl desmopressin (DPP), and to compare its anti-diuretic efficacy and biodistribution with that of unmodified desmopressin (DDAVP).
METHODS: Dithiothreitol (DTT) was used to reduce the intramolecular disulfide bond in DDAVP, and the reduced DDAVP was treated with a thiopyridine-containing disulfide lipidization reagent, Pal-CPD. The product, DPP, was purified by acid precipitation and, subsequently, by size-exclusion chromatography. Reversed-phase HPLC was used to analyze the purity and to evaluate the hydrophobicity of the product. Mass spectrometry was employed to characterize its molecular structure. The biological activity of DPP was demonstrated by the antidiuretic effects in vasopressin-deficient Brattleboro rats. Preliminary pharmacokinetic and biodistribution studies of intravenously injected DDAVP and DPP were carried out in CF-1 mice.
RESULTS: DDAVP was readily reduced by a 2-fold molar excess of DTT at 37 degrees C for 0.5 hr. DPP was formed by the reaction of reduced DDAVP with Pal-CPD. Each DPP molecule contains two palmitic acid moieties, which link to the peptide via two disulfide bonds. After acid precipitation and size-exclusion chromatography, the purity was found to be approximately 95%, and the overall yield was 57%. When DPP was administered subcutaneously to Brattleboro rats, the potency of the anti-diuretic activity of DDAVP was enhanced to more than 250-fold. The plasma concentration of intravenously injected DDAVP in mice decreased rapidly during the first 20 min and followed by a slow elimination rate. However, in DPP administered mice, the plasma concentration actually increased in the first 20 min, followed by a slow elimination with a rate similar to that in DDAVP-injected mice. The regeneration of DDAVP was detected in the plasma of mice treated with DPP. Studies of the organ distribution in mice indicated that the liver retention of DPP was longer than that of DDAVP. On the other hand, the intestinal excretion of DPP was significantly less than that of DDAVP.
CONCLUSIONS: The 250-fold increase of the anti-diuretic potency in DPP is most likely due to a slow elimination and prolonged tissue retention, together with the regeneration of active DDAVP, in the animals. Our results indicate that reversible lipidization is a simple and effective approach for improving the efficacy of many peptide drugs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10571271     DOI: 10.1023/a:1018929312715

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

1.  Recombinant human growth hormone poly(lactic-co-glycolic acid) microsphere formulation development.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1997-10-13       Impact factor: 15.470

2.  Transport of hydrophobized fragments of antibodies through the blood-brain barrier.

Authors:  V P Chekhonin; I A Ryabukhin; Y A Zhirkov; I A Kashparov; T B Dmitriyeva
Journal:  Neuroreport       Date:  1995-12-29       Impact factor: 1.837

3.  Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus.

Authors:  I Vávra; A Machová; V Holecek; J H Cort; M Zaoral; F Sorm
Journal:  Lancet       Date:  1968-05-04       Impact factor: 79.321

4.  Comparison of pharmacokinetic parameters of a polypeptide, the Bowman-Birk protease inhibitor (BBI), and its palmitic acid conjugate.

Authors:  L Honeycutt; J Wang; H Ekrami; W C Shen
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

5.  Radioiodination by use of the Bolton-Hunter and related reagents.

Authors:  J J Langone
Journal:  Methods Enzymol       Date:  1980       Impact factor: 1.600

6.  The discovery of the Brattleboro rat, recommended nomenclature, and the question of proper controls.

Authors:  H Valtin
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

7.  Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.

Authors:  M Manning; L Balaspiri; J Moehring; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1976-06       Impact factor: 7.446

8.  Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides.

Authors:  H M Ekrami; A R Kennedy; W C Shen
Journal:  FEBS Lett       Date:  1995-09-11       Impact factor: 4.124

9.  Phospholipid prodrug inhibitors of the HIV protease. Antiviral activity and pharmacokinetics in rats.

Authors:  K Y Hostetler; D D Richman; E A Forssen; L Selk; R Basava; M F Gardner; S Parker; C Basava
Journal:  Biochem Pharmacol       Date:  1994-10-07       Impact factor: 5.858

10.  Structure of pressinoic acid: the cyclic moiety of vasopressin.

Authors:  D A Langs; G D Smith; J J Stezowski; R E Hughes
Journal:  Science       Date:  1986-06-06       Impact factor: 47.728

View more
  9 in total

Review 1.  Strategic approaches to optimizing peptide ADME properties.

Authors:  Li Di
Journal:  AAPS J       Date:  2014-11-04       Impact factor: 4.009

2.  Influence of acylation on the adsorption of insulin to hydrophobic surfaces.

Authors:  Charlotte Pinholt; Susanne Hostrup; Jens Thostrup Bukrinsky; Sven Frokjaer; Lene Jorgensen
Journal:  Pharm Res       Date:  2010-12-29       Impact factor: 4.200

3.  Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide.

Authors:  Liyun Yuan; Jeff Wang; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

Review 4.  Derivatization with fatty acids in peptide and protein drug discovery.

Authors:  Peter Kurtzhals; Søren Østergaard; Erica Nishimura; Thomas Kjeldsen
Journal:  Nat Rev Drug Discov       Date:  2022-08-24       Impact factor: 112.288

5.  Phase behavior and nanoscale structure of phospholipid membranes incorporated with acylated C14-peptides.

Authors:  Tina B Pedersen; Thomas Kaasgaard; Morten Ø Jensen; Sven Frokjaer; Ole G Mouritsen; Kent Jørgensen
Journal:  Biophys J       Date:  2005-08-12       Impact factor: 4.033

Review 6.  Fatty acids as therapeutic auxiliaries for oral and parenteral formulations.

Authors:  Michael J Hackett; Jennica L Zaro; Wei-Chiang Shen; Patrick C Guley; Moo J Cho
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

7.  Structure-activity relationship of reversibly lipidized peptides: studies of fatty acid-desmopressin conjugates.

Authors:  Jeff Wang; Daphne Wu; Wei-Chiang Shen
Journal:  Pharm Res       Date:  2002-05       Impact factor: 4.200

8.  Aqueous-soluble, non-reversible lipid conjugate of salmon calcitonin: synthesis, characterization and in vivo activity.

Authors:  Weiqiang Cheng; Seetharama Satyanarayanajois; Lee-Yong Lim
Journal:  Pharm Res       Date:  2006-11-16       Impact factor: 4.580

Review 9.  Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.

Authors:  Renata Kowalczyk; Paul W R Harris; Geoffrey M Williams; Sung-Hyun Yang; Margaret A Brimble
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.